Barclays’s Guardant Health GH Stock Holding History

Barclays’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-50,100	Closed	-$3.84M	–	7043
2019 Q1	$3.84M	Buy	+50,100	New	+$2.78M	﹤0.01%	1894

Other funds holding GH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays's GH Position: Q1 2026 in Review

Barclays reduced its Guardant Health (GH) stake by 24% in Q1 2026, selling an estimated $8.26M and leaving 253,959 shares worth $23.5M. The position accounts for 0.01% of the portfolio, ranked #1027.

Barclays first reported a position in GH in Q4 2018 and has held it in 30 quarters since. The position peaked at $34.3M in Q4 2025. 482 funds tracked by Wall St. Rank hold GH as of Q1 2026.

Barclays held 253,959 shares of Guardant Health worth $23.5M as of Q1 2026.
Barclays sold 82,315 Guardant Health shares in Q1 2026, an estimated $8.26M.
Guardant Health made up 0.01% of Barclays's portfolio in Q1 2026, its #1027 holding.
Barclays first reported a position in Guardant Health in Q4 2018 and has held it in 30 quarters since.
Barclays's Guardant Health position peaked at $34.3M in Q4 2025.
482 funds tracked by Wall St. Rank held Guardant Health as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.